医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Three More Patents Issued for Mannatech

2014年09月05日 AM01:00
このエントリーをはてなブックマークに追加


 

COPPELL, Texas

Mannatech®, Incorporated (NASDAQ: MTEX), the pioneer of nutritional glycobiology and leading innovator of naturally sourced supplements based on Real Food Technology® solutions, and creator of the M5MSM (Mission 5 MillionSM) social entrepreneurial movement, announced the issuance of two new patents in Australia and one in Japan on product technologies. In total, Mannatech holds 96 patents worldwide.

One of the issued patents applies to Mannatech’s PhytoMatrix® formulation (titled All Natural Multivitamin and Multimineral Dietary Supplement Formulations for Enhanced Absorption and Biological Utilization). PhytoMatrix caplets are based on Mannatech’s Real Food Technology solutions, which provide standardized levels of nutrients sourced from fruits, vegetables and plants.* To date, six patents have been issued worldwide for the technology pertaining to Mannatech’s PhytoMatrix formulation.

Two of the patents issued apply to Mannatech’s Ambrotose AO® formulation (one issued in Australia and another in Japan). Ambrotose AO capsules provide a blend of plant extracts and antioxidant compounds with vitamins C and E to help the body combat oxidative stress. Just two capsules a day are scientifically validated to provide over two and a half times more antioxidant protection than five servings of fruits and vegetables.* To date, 31 patents have been issued worldwide to Mannatech for the technology pertaining to its Ambrotose AO formulation.

“A pillar of Mannatech from the very beginning has been product innovation,” commented Dr. Robert A. Sinnott, CEO and Chief Science Officer of Mannatech. “Our robust and ever-expanding patent portfolio tangibly shows our continued commitment to innovation. Our systematic approach to research and intellectual property development is a constant part of our everyday efforts at the company. It serves as a huge asset to both the company and its thousands of Independent Associates.”

Anyone interested in learning more about Mannatech can visit Mannatech.com. To review publications, studies and other scientific information regarding the company’s products, visit MannatechScience.org.

About Mannatech

Mannatech, Incorporated, develops high-quality health, weight and fitness, and skin care products that are based on the solid foundation of nutritional science and development standards. Mannatech is dedicated to its platform of Social Entrepreneurship based on the foundation of promoting, aiding and optimizing nutrition where it is needed most around the world. Mannatech’s proprietary products are available through independent sales Associates around the globe including the United States, Canada, South Africa, Australia, New Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan, Taiwan, Singapore, Estonia, Finland, the Republic of Ireland, Czech Republic, the Republic of Korea, Mexico, Namibia and Hong Kong. For more information, visit Mannatech.com.

Please note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “believe,” “intend” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain Associates and Members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

CONTACT

Mannatech, Incorporated
Ben Hulet, 972-471-7224
bhulet@mannatech.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表